MKMasaomi Kuwada

Masaomi Kuwada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaomi Kuwada has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE Trial

    by Makito Miyake, Satoshi Anai, Yusuke Iemura, Kazuki Ichikawa, Tatsuki Miyamoto, Atsushi Tomioka, Masaomi Kuwada, Yoshitaka Itami, Yukinari Hosokawa, Yoshiaki Matsumura, et al.

    Unresectable, metastatic, advanced urothelial carcinoma (aUC) is an aggressive disease and is treated with platinum-containing first-line chemotherapy, followed by immune checkpoint inhibitors and antibody–drug conjugates. Response to first-line chemotherapy is a vital priority in sequential treatment strategies because a better response to first-line chemotherapy is associated with a better response to subsequent therapies. Gemcitabine plus carboplatin chemotherapy is conventionally recommended for cisplatin-ineligible patients. This multicenter, single-arm prospective trial will investigate whether dose-dense methotrexate, vinblastine, doxorubicin, and carboplatin (DD-MVACarbo) chemotherapy is superior to gemcitabine plus carboplatin chemotherapy in terms of efficacy in platinum-naïve, cisplatin-ineligible patients with aUC. After screening and registration, a total of 46 patients will be treated with this novel chemotherapy regimen. The primary endpoint is the objective response rate. The secondary endpoints include disease control rate, patient-reported outcomes, and adverse events. No evidence of this novel intervention is available as of July 2024. The results are expected to change the standard of care and improve the management of patients with aUC.


  • Open Access

    Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer

    by Fumisato Maesaka, Masaomi Kuwada, Shohei Horii, Shingo Kishi, Rina Fujiwara-Tani, Shiori Mori, Kiyomu Fujii, Takuya Mori, Hitoshi Ohmori, Takuya Owari, et al.

    The tight junction (TJ) protein claudin-4 (CLDN4) is overexpressed in bladder urothelial carcinoma (BUC) and correlates with cancer progression. However, the mechanism of CLDN4 upregulation and promotion of malignant phenotype is not clear. Here, we analyzed 157 cases of BUC and investigated the hypomethylation of CpG island in the CLDN4 promoter DNA and its correlation with cancer progression. In hypomethylated cases, CLDN4 expression, cell proliferation, stemness, and epithelial-mesenchymal transition were increased. Treatment of three human BUC cell lines with the demethylating agent aza-2′-deoxycytidine (AZA) led to excessive CLDN4 expression, and, specifically, to an increase in CLDN4 monomer that is not integrated into the TJ. The TJ-unintegrated CLDN4 was found to bind integrin β1 and increase stemness, drug resistance, and metastatic ability of the cells as well as show an anti-apoptosis effect likely via FAK phosphorylation, which reduces upon knockdown of CLDN4. Thus, CLDN4 is overexpressed in BUC by an epigenetic mechanism and the high expression enhances the malignant phenotype of BUC via increased levels of TJ-unintegrated CLDN4. CLDN4 promoter DNA methylation is expected to be a novel indicator of BUC malignant phenotype and a new therapeutic target.


  • Open Access

    The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

    by Makito Miyake, Masaomi Kuwada, Shunta Hori, Yosuke Morizawa, Yoshihiro Tatsumi, Satoshi Anai, Yukinari Hosokawa, Yoshiki Hayashi, Atsushi Tomioka, Takeshi Otani, et al.

    The aim of this study is to investigate the prognostic relevance of the best objective response of metastatic target lesions during sunitinib treatment in patients with metastatic renal cell carcinoma. Radiographic analysis of the best objective response according to the Response Evaluation Criteria in Solid Tumors was assessed in 50 patients. Clinicopathological characteristics including the Heng risk classification and sunitinib-related adverse reactions were compared among four patient subgroups [complete response or partial response (CR/PR), stable disease (SD), progressive disease (PD), and those without treatment evaluation (NE)]. Kaplan–Meier and Cox proportional regression analyses of progression-free survival and overall survival were performed to identify prognostic variables. The best objective response was CR/PR in 12 (24 %) patients, SD in 22 (44 %), PD in 6 (12 %), and NE in 10 (20 %). The incidence of hypertension and hypothyroidism was associated with a better objective response. Progression-free survival was 15.0, 9.2, 6.8, and 2.2 months in the CR/PR, SD, PD, and NE groups, respectively (P = 0.0004, log-rank test), while the corresponding median overall survival was 59.7, 24.2, 17.1, and 18.1 months, respectively (P = 0.007). Multivariate analysis revealed that hazard ratios for risk of death of the SD, PD, and NE groups were 4.51 (P = 0.06), 7.93 (P = 0.02), and 4.88 (P = 0.04), respectively, as compared to the CR/PR group. Our findings suggested that the best objective response of target lesions was a prognostic marker for both progression-free survival and overall survival in sunitinib treatment. Furthermore, the incidence of sunitinib-induced hypertension was associated with a longer progression-free survival.


    • 1 September 2015
      • Vol. 61  (9) , 359-63

    [Ex Vivo Partial Nephrectomy and Auto-Transplantation of a Solitary Kidney with Metastatic Renal Cell Carcinoma : A Case Report].

    by Takuya Owari, Katsunori Yoshida, Tatsuo Yoneda, Takashi Iwamoto, Shunta Hori, Yousuke Morizawa, Masaomi Kuwada, Makito Miyake, Kazumasa Torimoto, Katsuya Aoki, et al.

    A 68-year-old man underwent radical nephrectomy for renal cell carcinoma of the right kidney 12 years ago. He was diagnosed as having a recurrent tumor of the contralateral kidney and a single metastatic pulmonary lesion by diagnostic imaging on the annual checkup. He visited us in order to receive nephron sparing surgery. Since the preoperative abdominal computed tomography showed tumor thrombus invading into the intrarenal vein, ex vivo partial nephrectomy and auto-transplantation was performed. Although he received transit hemodialysis during the postoperative 10 days, his renal function, thereafter became stable without hemodialysis. Eighty-seven days later he underwent right lower lobectomy. At postoperative 6 months he has no local recurrence or distant metastasis and maintains well-preserved renal function.

  • Open Access

    Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid

    by Yasushi Nakai, Satoshi Anai, Masaomi Kuwada, Makito Miyake, Yoshitomo Chihara, Nobumichi Tanaka, Akihide Hirayama, Katsunori Yoshida, Yoshihiko Hirao, Kiyohide Fujimoto

    Past attempts at detecting prostate cancer (PCa) cells in voided urine by traditional cytology have been impeded by undesirably low sensitivities but high specificities. To improve the sensitivities, we evaluate the feasibility and clinical utility of photodynamic diagnosis (PDD) of prostate cancer by using 5-aminolevulinic acid (5-ALA) to examine shed prostate cancer cells in voided urine samples.


  • Open Access

    Novel missense mutation in the FH gene in familial renal cell cancer patients lacking cutaneous leiomyomas

    by Masaomi Kuwada, Yoshitomo Chihara, Yi Lou, Kazumasa Torimoto, Yoriaki Kagebayashi, Kenji Tamura, Taro Shuin, Kiyohide Fujimoto, Hiroki Kuniyasu, Shoji Samma

    Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare tumor predisposition syndrome characterized by cutaneous and uterine leiomyomas and papillary type 2 renal cell cancer. Germline mutation of the fumarate hydratase (FH) gene is known to be associated with HLRCC.


    • 1 September 2012
      • Vol. 58  (9) , 507-9

    [A case of persistent Mullerian duct syndrome diagnosed by laparoscopic examination for impalpable testis].

    by Daisuke Goto, Katsuya Aoki, Kenji Otsuka, Masaomi Kuwada, Katsunori Yoshida, Kiyohide Fujimoto, Yoshihiko Hirao

    Persistent mullerian duct syndrome describes a group of patients with a 46 XY karyotype and normal male external genitalia, but internal mullerian structures. A 7-month-old boy presented with a left inguinal hernia, a left undescended testis and a right impalpable testis. Inguinal herniorrhaphy was performed and laparoscopy was done for search of a right impalpable testis and internal genitalia simultaneously. Laparoscopic examination revealed the structure like a mullerian duct remnant along the left spermatic duct in rectovesical fossa and right intra-abdominal testis. The structure like a mullerian duct remnant was not removed to preserve the left spermatic duct. Left orchiopexy and right laparoscopic staged Fowler- Stephens orchiopexy were performed. Chromosomal analysis was 46 XY karyotype and we diagnosed this case as persistent mullerian duct syndrome.

    • 1 January 2010
      • Vol. 56  (1) , 17-20

    [A case of acute pulmonary thromboembolism after retroperitoneoscopic nephrectomy : a case report].

    by Masaomi Kuwada, Yukinari Hosokawa, Motokiyo Yoshikawa, Satoshi Takada, Hiromi Kumamoto, Yoshiki Hayashi, Nobuo Oyama, Kiyohide Fujimoto, Yoshihiko Hirao

    A 65-year old woman underwent retroperitoneoscopic nephrectomy, for left renal mass which was suspected to be renal cell carcinoma. On the 2nd postoperation day, she suddenly complained of dyspnea and chest pain. Enhanced computed tomography revealed a defect of peripheral pulmonary artery, and ventilation-perfusion lung scanning showed large defect of the uptake in bilateral lung fields. Based on the arterial blood gas and imagings, she was diagnosed with a PTE (pulmonary thromboembolism). Thrombolytic therapy and anti-coagulant therapy were started. Thereafter, she recovered from hypoxia. However, these therapies gave rise to postoperative hemorrhage resulting in a massive retroperitoneal hematoma.

    • 1 October 2009
      • Vol. 55  (10) , 599-602

    [Adrenocortical carcinoma with intratumoral hemorrhage detected from chest and back pain: a case report].

    by Masaomi Kuwada, Yukinari Hosokawa, Satoshi Takada, Hiromi Kumamoto, Yoshiki Hayashi, Kiyohide Fujimoto, Yoshihiko Hirao

    A 55-year-old man visited our hospital with left chest and back pain. Computed tomography (CT) showed left retroperitoneal tumor, which was 6 cm in diameter with intratumoral hemorrhage. Based on abdominal CT, magnetic resonance imaging and blood tests, preoperative diagnosis was adrenocortical carcinoma. En bloc resection of the tumor and the left kidney was performed. The histological diagnosis was adrenocortical carcinoma. He rejected adjuvant therapy with mitotane. Bone and liver metastases were recognized 2 months after operation. The patient died three months after operation because of disease progression.

    • 1 August 2008
      • Vol. 54  (8) , 561-3

    [Case of sarcomatoid carcinoma of the urinary bladder].

    by Yukinari Hosokawa, Masaomi Kuwada, Hiromi Kumamoto, Yoshiki Hayashi, Kiyohide Fujimoto, Yoshihiko Hirao

    A 57-year-old man was referred to our hospital for bladder tumor. The computed tomographic scan demonstrated an 8 cm solid mass in the posterior wall of the bladder. Cystoscopy revealed a non-papillary large bulky tumor and a necrotic tumor surface. The tumor was transurethrally resected and its histology showed sarcomatoid carcinoma composed of a urothelial cell carcinoma. Total cystectomy was performed and an ileal neobladder was constructed. He now shows no evidence of disease 43 months after the operation.